453 related articles for article (PubMed ID: 15908059)
1. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
Larrauri A; Cano R; García M; Mateo Sd
Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
[TBL] [Abstract][Full Text] [Related]
2. Meningococcal C vaccines: the Canadian experience.
De Wals P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
[TBL] [Abstract][Full Text] [Related]
3. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.
Trotter CL; Andrews NJ; Kaczmarski EB; Miller E; Ramsay ME
Lancet; 2004 Jul 24-30; 364(9431):365-7. PubMed ID: 15276396
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.
Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M
Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929
[TBL] [Abstract][Full Text] [Related]
6. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
8. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
[TBL] [Abstract][Full Text] [Related]
9. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
[TBL] [Abstract][Full Text] [Related]
11. [Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination].
Gutiérrez Rodríguez MA; Ramírez Fernández R; García Gutiérrez J; Moreno Civantos A; Hernando García M; Arce Arnáez A; Sendra Gutiérrez JM; Bueno Vallejos R
Rev Esp Salud Publica; 2000; 74(4):397-403. PubMed ID: 11031849
[TBL] [Abstract][Full Text] [Related]
12. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
Pace D
Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
[TBL] [Abstract][Full Text] [Related]
13. The impact of meningococcal serogroup C conjugate vaccine in Scotland.
Mooney JD; Christie P; Robertson C; Clarke SC
Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001
[TBL] [Abstract][Full Text] [Related]
14. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
Cohen R; Levy C
Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
[TBL] [Abstract][Full Text] [Related]
15. Meningococcal C conjugate age-dependant long-term loss of effectiveness.
Garrido-Estepa M; Nuñez OG; León-Gómez I; Cano R; Herruzo R
Vaccine; 2015 May; 33(19):2221-2227. PubMed ID: 25819711
[TBL] [Abstract][Full Text] [Related]
16. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
Pollard AJ; Green C; Sadarangani M; Snape MD
Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919
[No Abstract] [Full Text] [Related]
17. Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis.
Bettinger JA; Scheifele DW; Halperin SA; Kellner JD; Vanderkooi OG; Schryvers A; De Serres G; Alcantara J
Vaccine; 2012 Jun; 30(27):4023-7. PubMed ID: 22537988
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.
De Wals P; Nguyen VH; Erickson LJ; Guay M; Drapeau J; St-Laurent J
Vaccine; 2004 Mar; 22(9-10):1233-40. PubMed ID: 15003652
[TBL] [Abstract][Full Text] [Related]
19. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
20. Meningococcal disease: a review on available vaccines and vaccines in development.
Bröker M; Fantoni S
Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]